Literature DB >> 24687824

Will focal therapy remain only an attractive illusion for the primary treatment of prostate cancer?

Gianluca Giannarini1, Giorgio Gandaglia, Francesco Montorsi, Alberto Briganti.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24687824     DOI： 10.1200/JCO.2013.54.8214

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  10 in total

1.  Dosimetric benefits of hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy.

Authors:  Amar U Kishan; Sang J Park; Christopher R King; Kristofer Roberts; Patrick A Kupelian; Michael L Steinberg; Mitchell Kamrava
Journal:  Br J Radiol       Date:  2015-10-14       Impact factor: 3.039

2.  Utility of Multiparametric MRI for Predicting Residual Clinically Significant Prostate Cancer After Focal Laser Ablation.

Authors:  Ely R Felker; Steven S Raman; David S K Lu; Mitch Tuttle; Daniel J Margolis; Fuad F ElKhoury; James Sayre; Leonard S Marks
Journal:  AJR Am J Roentgenol       Date:  2019-07-30       Impact factor: 3.959

Review 3.  Vascular targeted photochemotherapy using padoporfin and padeliporfin as a method of the focal treatment of localised prostate cancer - clinician's insight.

Authors:  Andrzej M Bugaj
Journal:  World J Methodol       Date:  2016-03-26

Review 4.  Functional magnetic resonance imaging and molecular pathology at the crossroad of the management of early prostate cancer.

Authors:  Raphaele Renard-Penna; Geraldine Cancel-Tassin; Eva Comperat; Morgan Roupret; Pierre Mozer; Olivier Cussenot
Journal:  World J Urol       Date:  2015-05-06       Impact factor: 4.226

5.  Validation of the current eligibility criteria for focal therapy in men with localized prostate cancer and the role of MRI.

Authors:  Raisa S Pompe; Bieke Kühn-Thomä; Yamini Nagaraj; Valia Veleva; Felix Preisser; Sami-Ramzi Leyh-Bannurah; Markus Graefen; Hartwig Huland; Derya Tilki; Georg Salomon
Journal:  World J Urol       Date:  2018-02-28       Impact factor: 4.226

6.  Pilot Study to Assess Safety and Clinical Outcomes of Irreversible Electroporation for Partial Gland Ablation in Men with Prostate Cancer.

Authors:  Katie S Murray; Behfar Ehdaie; John Musser; Joseph Mashni; Govindarajan Srimathveeravalli; Jeremy C Durack; Stephen B Solomon; Jonathan A Coleman
Journal:  J Urol       Date:  2016-04-23       Impact factor: 7.450

7.  Improved specificity with 68Ga PSMA PET/CT to detect clinically significant lesions "invisible" on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology.

Authors:  Peter Donato; Matthew J Roberts; Andrew Morton; Samuel Kyle; Geoff Coughlin; Rachel Esler; Nigel Dunglison; Robert A Gardiner; John Yaxley
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-19       Impact factor: 9.236

8.  Bright insights into palladium-triggered local chemotherapy.

Authors:  Thomas L Bray; Mark Salji; Alessandro Brombin; Ana M Pérez-López; Belén Rubio-Ruiz; Laura C A Galbraith; E Elizabeth Patton; Hing Y Leung; Asier Unciti-Broceta
Journal:  Chem Sci       Date:  2018-07-17       Impact factor: 9.825

Review 9.  The challenging landscape of medical device approval in localized prostate cancer.

Authors:  Massimo Valerio; Mark Emberton; Scott E Eggener; Hashim U Ahmed
Journal:  Nat Rev Urol       Date:  2015-12-15       Impact factor: 14.432

10.  Prospective evaluation of fexapotide triflutate injection treatment of Grade Group 1 prostate cancer: 4-year results.

Authors:  Neal Shore; Steven A Kaplan; Ronald Tutrone; Richard Levin; James Bailen; Alan Hay; Susan Kalota; Mohamed Bidair; Sheldon Freedman; Kenneth Goldberg; Frederick Snoy; Jonathan I Epstein
Journal:  World J Urol       Date:  2020-02-22       Impact factor: 4.226
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.